FDA Grants Priority Review to Genentech's Tecentriq Monotherapy as First-line Treatment of Certain People With Advanced Non-small Cell Lung Cancer - Odessa American

FDA Grants Priority Review to Genentech's Tecentriq Monotherapy as First-line Treatment of Certain People With Advanced Non-small Cell Lung Cancer  Odessa American